During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the MDS Hub spoke to Raphael Itzykson, Université de Paris, Paris, FR, about the phase III Dacota trial. We asked, Will hydroxyurea remain standard of care for advanced proliferative chronic myelomonocytic leukemia (CMML)?
The MDS Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Phase III Dacota trial: Will hydroxyurea remain SoC for advanced proliferative CMML?
Phase III Dacota trial: Will hydroxyurea remain SoC for advanced proliferative CMML?
Itzykson discusses the results from the randomized phase III Dacota trial evaluating decitabine versus hydroxyurea in patients with advanced proliferative CMML.
More about...
Related articles
Newsletter
Subscribe to get the best content related to MDS delivered to your inbox